Unveiling Glioblastoma Immunosuppression Rescued by Allergy through Multi-Omic Analysis

Glioblastoma (GBM) poses significant therapeutic challenges due to its aggressive nature and resistance to conventional treatments. Immunotherapy holds promise for GBM treatment; however, the tumor's immunosuppressive microenvironment limits its efficacy. Intriguingly, epidemiological data hint at a protective effect of allergic diseases against GBM development,
prompting further investigation into potential therapeutic avenues. Our previous work successfully demonstrated the protective influence of allergic inflammation on gliomagenesis in murine models, revealing its ability to counteract immunosuppression and promote anti-tumoral immune responses. Building upon this foundation, our current project aims to unravel the molecular mechanisms underlying the reversal of GBM-associated immunosuppression by allergic inflammation. Leveraging both our mouse model and multi-omic data from a cohort of pre-diagnosed glioma patients, we seek to elucidate the intricate interplay between allergic inflammation and the immune response in GBM. Through integrative analysis of transcriptomic, proteomic, and metabolomic data, we endeavor to identify pivotal molecular
pathways and therapeutic targets. Ultimately, our findings aspire to unveil novel strategies for mitigating GBM immunosuppression and augmenting the efficacy of immunotherapy, offering renewed hope for patients afflicted by this devastating disease.